8 hours ago
1
Dr. Reddy’s Laboratories announced connected Saturday (June 13, 2026 ) the first-to-market motorboat of Bosutinib Tablets 400 mg, a generic equivalent of Pfizer subsidiary Wyeth’s crab cause Bosulif, successful the U.S.
Bosutinib Tablets (400mg) was a first-to-file merchandise and frankincense eligible for 180-days of generic cause exclusivity for this strength, successful the U.S., Dr. Reddy’s said.
For the product, it had collaborated with different Hyderabad-based generic drugmaker MSN Laboratories. While the exclusive selling rights for the merchandise successful the U.S. remainder with Dr. Reddy’s, MSN is liable for the improvement and manufacturing of the product, the institution said.
The Bosulif marque (400 mg) had U.S. income of astir $253.8 cardinal for the latest 12-month play ended April 2026, it said, citing IQVIA National Sales Perspectives data.
“With this launch, we stay focused connected strengthening our oncology portfolio and partnering crossed the healthcare strategy to guarantee that captious treatments are some accessible and affordable,” CEO- North America of Dr. Reddy’s Milan Kalawadia said.
The palmy improvement and commercialisation of Bosutinib Tablets demonstrates MSN’s beardown scientific, regulatory, and manufacturing capabilities successful analyzable oncology products, said Bharat Reddy, Executive Director of MSN Laboratories.
According to the U.S. FDA, Bosulif is simply a kinase inhibitor indicated for the attraction of big patients with newly-diagnosed chronic signifier Ph+ chronic myelogenous leukemia (CML); and chronic, accelerated oregon blast signifier Ph+ CML with absorption oregon intolerance to anterior therapy.
